Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immuneering (IMRX) Share-based Compensation (2020 - 2024)

Immuneering has reported Share-based Compensation over the past 5 years, most recently at $1.7 million for Q4 2024.

  • Quarterly results put Share-based Compensation at $1.7 million for Q4 2024, up 5.13% from a year ago — trailing twelve months through Dec 2024 was $6.5 million (up 13.52% YoY), and the annual figure for FY2025 was $6.3 million, down 2.93%.
  • Share-based Compensation for Q4 2024 was $1.7 million at Immuneering, up from $1.6 million in the prior quarter.
  • Over the last five years, Share-based Compensation for IMRX hit a ceiling of $1.7 million in Q4 2024 and a floor of $182225.0 in Q1 2021.
  • Median Share-based Compensation over the past 5 years was $1.1 million (2022), compared with a mean of $995273.5.
  • Biggest five-year swings in Share-based Compensation: surged 392.61% in 2022 and later grew 5.13% in 2024.
  • Immuneering's Share-based Compensation stood at $216607.0 in 2020, then surged by 192.04% to $632583.0 in 2021, then skyrocketed by 65.7% to $1.0 million in 2022, then soared by 56.52% to $1.6 million in 2023, then rose by 5.13% to $1.7 million in 2024.
  • The last three reported values for Share-based Compensation were $1.7 million (Q4 2024), $1.6 million (Q3 2024), and $1.7 million (Q2 2024) per Business Quant data.